LEVIN CAPITAL STRATEGIES, L.P.
Position in ALLO — Allogene Therapeutics, Inc.
CIK 1354821
NEW YORK, NY
Position in ALLO
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$32,025
+$14,044 QoQ
Shares Held
13,125
0.0% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ALLO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LEVIN CAPITAL STRATEGIES, L.P. holds $12,744,736 across 8 Biotechnology names. ALLO ranks #8 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AURA |
Aura Biosciences, Inc.
|
941,400 | $6,297,966 | |
| 2 | SPRY |
ARS Pharmaceuticals, Inc.
|
552,561 | $4,437,064 | |
| 3 | DRTS |
Alpha Tau Medical Ltd.
|
106,423 | $752,410 | |
| 4 | SMMT |
Summit Therapeutics Inc.
|
37,676 | $714,336 | |
| 5 | EYPT |
EyePoint, Inc.
|
31,500 | $406,035 | |
| 6 | IMRX |
Immuneering Corp
|
10,000 | $52,700 | |
| 7 | PRME |
Prime Medicine, Inc.
|
15,000 | $52,200 | |
| 8 | ALLO |
Allogene Therapeutics, Inc.
This page
|
13,125 | $32,025 |
All Filings in ALLO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,025 | 13,125 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $17,981 | 13,125 | Shares | Other | 2026-01-30 | |
| 2025-09-30 | $65,100 | 52,500 | Shares | Other | 2025-11-07 | |
| No filing history on record for this holder in this stock. | ||||||